Press Releases

  • Jun 29, 2026

    Resalis Announces Initiation of Phase 1b Clinical Study Evaluating RES-010 as Treatment to Address Unmet Needs in Obesity

    View PDF

  • Jan 22, 2026

    Resalis Therapeutics Appoints Sandor Batkai as Medical Director

    View PDF

  • Oct 07, 2025

    Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings

    View PDF

  • Dec 03, 2024

    Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity

    View PDF

  • Oct 28, 2024

    Resalis Therapeutics Gains Strategic Equity Investment from Sanofi

    View PDF

  • Feb 1, 2024

    Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer

    View PDF

  • Jan 4, 2024

    Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity

    View PDF

  • Feb 22, 2023

    Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases

    View PDF

X